Canaccord lowered the firm’s price target on Bioceres to $12.50 from $17 and keeps a Buy rating on the shares. The firm said despite strong yyea-over-year growth across the board, the results missed both Canaccord’s top- and bottom-line estimates by ~8% and ~31%, respectively, and additionally missed consensus estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX: